(Q51763526)

11 April 2018

title

Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. (English)

1 reference

11 April 2018

0 references

Rasmus Goll

3

0 references

Anne Husebekk

series ordinal

4

object named as

Anne Husebekk

1 reference

11 April 2018

Trine Olsen

1

1 reference

11 April 2018

Guanglin Cui

series ordinal

2

1 reference

11 April 2018

Jon Florholmen

series ordinal

5

1 reference

11 April 2018

publication date

1 January 2009

1 reference

11 April 2018

Scandinavian Journal of Gastroenterology

published in

1 reference

11 April 2018

volume

44

1 reference

11 April 2018

issue

6

1 reference

11 April 2018

page(s)

727-735

1 reference

11 April 2018

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

cites work

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Cytokine/chemokine transcript profiles reflect mucosal inflammation in Crohn?s disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Tissue cytokine and chemokine expression in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

New insights into the pathogenesis of inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

The immunological and genetic basis of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Review article: Infliximab therapy for inflammatory bowel disease--seven years on

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNF-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Evaluation of absolute quantitation by nonlinear regression in probe-based real-time PCR

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Reduced expression of microenvironmental Th1 cytokines accompanies adenomas-carcinomas sequence of colorectum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Type 1 T-helper cell predominance in granulomas of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Tumor necrosis factor: biology and therapeutic inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Is irritable bowel syndrome an inflammatory disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F00365520902803507

10.1080/00365520902803507

21 January 2018

Identifiers

DOI

1 reference

11 April 2018

1 reference

11 April 2018